布鲁氏菌病(布病)是由布鲁氏菌感染引起的人畜共患传染病,迄今为止动物间布病尚未根除,且缺乏安全有效的人体疫苗,因此,"早期、联合、足量、足疗程"的药物治疗仍然是人间布病管理中的重要策略。布病治疗目标为缓解和缩短症状期,减少并发症,防止复发以及转为慢性等。目前,尽管抗感染治疗对于大部分患者效果良好,但仍有一部分患者发生治疗失败或后期复发等情况,因此,布病的治疗策略亟待优化。本文阐述了布病治疗原则、临床治疗现状及未来发展趋势,以期为优化布病药物治疗方法提供参考。 Brucellosis is a zoonotic infectious disease caused by Brucella infection. So far, animal to animal Brucellosis has not been eradicated, and there is a lack of safe and effective human vaccine. Therefore, "early, combined, sufficient, and full course" drug treatment remains an important strategy in the management of human Brucellosis. The goal of treating brucellosis is to alleviate and shorten the symptom period, reduce complications, relapses, and chronicity. At present, although antibiotic treatment is effective for most patients, there are still some patients who experience treatment failure or later recurrence, so the treatment strategy for brucellosis urgently needs to be optimized. This article elaborates on the treatment principles, clinical treatment status, and future development trends of brucellosis, in order to provide references for optimizing drug treatment methods for brucellosis.
Brucellosis is a zoonotic infectious disease caused by Brucella infection. So far, animal to animal Brucellosis has not been eradicated, and there is a lack of safe and effective human vaccine. Therefore, "early, combined, sufficient, and full course" drug treatment remains an important strategy in the management of human Brucellosis. The goal of treating brucellosis is to alleviate and shorten the symptom period, reduce complications, relapses, and chronicity. At present, although antibiotic treatment is effective for most patients, there are still some patients who experience treatment failure or later recurrence, so the treatment strategy for brucellosis urgently needs to be optimized. This article elaborates on the treatment principles, clinical treatment status, and future development trends of brucellosis, in order to provide references for optimizing drug treatment methods for brucellosis.